Century Therapeutics, Inc.
$2.34
▼
-2.74%
2026-04-21 07:34:01
www.centurytx.com
NCM: IPSC
Explore Century Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$467.28 M
Current Price
$2.34
52W High / Low
$3.04 / $0.43
Stock P/E
—
Book Value
$1.82
Dividend Yield
—
ROCE
-5.16%
ROE
-5.98%
Face Value
—
EPS
$-0.14
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
78
Beta
1.67
Debt / Equity
27.41
Current Ratio
5.97
Quick Ratio
5.97
Forward P/E
-4.25
Price / Sales
3.7
Enterprise Value
$330.83 M
EV / EBITDA
-170.62
EV / Revenue
3.03
Rating
None
Target Price
$3
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Pluri Inc. | $3.59 | — | $36.08 M | — | -348.95% | 669.52% | $7.13 / $2.82 | $-1.46 |
| 2. | Spero Therapeutics, Inc. | $2.84 | 19.18 | $164.41 M | — | 11.92% | 16.3% | $3.22 / $0.57 | $1.05 |
| 3. | Opus Genetics, Inc. | $5.54 | — | $394.17 M | — | -90.9% | -2.42% | $5.81 / $0.71 | $0.22 |
| 4. | Alpha Cognition Inc. Common Stock | $6.89 | — | $150.02 M | — | -23.03% | -40.68% | $11.54 / $3.97 | $2.88 |
| 5. | 60 Degrees Pharmaceuticals, Inc. | $1.84 | — | $4.69 M | — | -220.2% | -2.01% | $17.68 / $1.29 | $-5.25 |
| 6. | BioCardia, Inc. | $1.25 | — | $12.91 M | — | -843.83% | -9.5% | $3.2 / $1 | $0.08 |
| 7. | Precigen, Inc. | $4.11 | — | $1.45 B | — | -90.19% | -5.72% | $5.46 / $1.23 | $0.06 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 109.16 M | 4.17 M | — |
| Operating Profit | -20.65 M | -29.36 M | -34.66 M | 74.18 M | -32.96 M | — |
| Net Profit | -19.17 M | -34.42 M | -32.54 M | 76.56 M | -36.07 M | — |
| EPS in Rs | -0.11 | -0.19 | -0.18 | 0.43 | -0.2 | -0.37 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 109.16 M | 6.59 M | 2.23 M | 5.2 M |
| Operating Profit | -10.51 M | -133.81 M | -125.18 M | -123.83 M |
| Net Profit | -9.58 M | -126.57 M | -136.67 M | -130.93 M |
| EPS in Rs | -0.05 | -0.7 | -0.76 | -0.73 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 223.7 M | 353.22 M | 360.69 M | 486.54 M |
| Total Liabilities | 64.77 M | 191.85 M | 175.94 M | 183.81 M |
| Equity | 158.94 M | 161.36 M | 184.75 M | 302.74 M |
| Current Assets | 120.77 M | 194.05 M | 176.99 M | 319.72 M |
| Current Liabilities | 20.23 M | 129.78 M | 17.85 M | 29.82 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -103.88 M | -110.14 M | -88.35 M | 14.05 M |
| Investing CF | 107.5 M | 47.48 M | 61.13 M | -13.13 M |
| Financing CF | 0.17 M | 74.56 M | -9.72 M | 27.16 M |
| Free CF | -104.72 M | -110.29 M | -102.08 M | -16.55 M |
| Capex | -0.85 M | -0.15 M | -13.74 M | -30.6 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 194.81% | -57.01% | — | — |
| Earnings Growth % | 7.4% | -4.38% | — | — |
| Profit Margin % | -1920.87% | -6115.12% | -2518.41% | — |
| Operating Margin % | -2030.81% | -5600.94% | -2381.82% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1828.9% | -5423.18% | -2331.24% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.